Thus, genetic variants that reduce OAS1 expression are likely to impair the degradation of SARS-CoV-2 RNA and antiviral responses triggered by NCM, which may contribute to the pathogenesis of severe COVID-19 illness. Here, OAS1 is linked to COVID-19.